Prognostic value of T-cell receptor γ rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas

References

• Armitage J O, Greer J P, Levine A M, Weisenburger D D, Formenti S C, Bast M, et al. Peripheral T-cell lymphoma. Cancer 1989; 63: 158–163
   PubMed Web of Science ®Google Scholar
• Armitage J O, Vose J M, Weisenburger D D. Towards understanding the peripheral T-cell lymphomas. Ann Oncol 2004; 15: 1447–1449
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Ralfkiaer E. Angioimmunoblastic lymphoma. pp 225 – 226, and Jaffe ES. Histological classification of mature T-cell and NK-cell neoplasms, pp 190 – 94. World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of the Haemaopoietic and Lymphoid Tisues. IARC Press, Lyon 2001
   Google Scholar
• Rüdiger T, Weisenburger D D, Anderson J R, Armitage J O, Diebold J, MacLennan K A, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140–149
   PubMed Web of Science ®Google Scholar
• Jaffe E S. Pathobiology of peripheral T-cell lymphomas. Hematol Am Soc Hematol Educ Program 2006; 1: 317–322
   Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76–82
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon P A, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990; 1: 45–50
   PubMed Web of Science ®Google Scholar
• Savage K J, Chhanabhai M, Gascoyne R D, Connors J M. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467–1475
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Ravandi F. Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol 2006; 43(2 Suppl 2)S27–S34, Review
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Lim Z, Pagliuca A, Salisbury J R, Mufti G J, Devereux S. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica 2006; 91(8 Suppl)ECR44
   PubMedGoogle Scholar
• Hotta T. Treatment of T-Cell lymphoma. Hematology 2005; 10(Suppl 1)193–196, Review
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Munsell M, Yazji S, Hagemeister F B, Younes A, Andersson B, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766–3770
   PubMed Web of Science ®Google Scholar
• Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533–1538
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald A P, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920–2924
   PubMed Web of Science ®Google Scholar
• Rodig S J, Abramson J S, Pinkus G S, Treon S P, Dorfman D M, Dong H Y, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006; 12: 7174–7179
   PubMed Web of Science ®Google Scholar
• Talpur R, Apisarnthanarax N, Ward S, Duvic M. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma 2002; 43: 121–126
   PubMed Web of Science ®Google Scholar
• Sonnen R, Schmidt W P, Muller-Hermelink H K, Schmitz N. The international prognostic index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005; 129: 366–372
   PubMed Web of Science ®Google Scholar
• Escalon M P, Liu N S, Yang Y, Hess M, Walker P L, Smith T L, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer 2005; 103: 2091–2098
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474–2479
   PubMed Web of Science ®Google Scholar
• Park P P, Ryoo B Y, Lee J H, Kwon H C, Yang S H, Kang H J, et al. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2007; 48: 716–722
   PubMed Web of Science ®Google Scholar
• Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004; 10: 5494–5500
   PubMed Web of Science ®Google Scholar
• Tsuchiya T, Ohshima K, Karube K, Yamaguchi T, Suefuji H, Hamasaki M, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 2004; 103: 236–241
   PubMed Web of Science ®Google Scholar
• Juarez T, Isenhath S N, Polissar N L, Sabath D E, Wood B, Hanke D, et al. Analysis of T-cell receptor gene rearrangement for predicting clinical outcome in patients with cutaneous T-cell lymphoma: a comparison of Southern blot and polymerase chain reaction methods. Arch Dermatol 2005; 141: 1107–1113, Erratum in: Arch Dermatol 2006;142:210
   PubMed Web of Science ®Google Scholar
• Tan B T, Warnke R A, Arber D A. The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn 2006; 8: 466–475, quiz 527
   PubMed Web of Science ®Google Scholar
• Födinger M, Buchmayer H, Schwarzinger I, Simonitsch I, Winkler K, Jager U, et al. Multiplex PCR for rapid detection of T-cell receptor-gamma chain gene rearrangements in patients with lymphoproliferative diseases. Br J Haematol 1996; 94: 136–139
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244, Erratum in: J Clin Oncol 2000;18:2351
   PubMed Web of Science ®Google Scholar
• van Dongen J J, Langerak A W, Bruggemann M, Evans P A, Hummel M, Lavender F L, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317
   PubMed Web of Science ®Google Scholar
• Trainor K J, Brisco M J, Wan J H, Neoh S, Grist S, Morley A A. Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood 1991; 78: 192–196
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Stablein D M, Carter W H, Jr, Novak J W. Analysis of survival data with nonproportional hazard functions. Control Clin Trials 1981; 2: 149–159
   PubMedGoogle Scholar
• Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V, et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 2002; 43: 805–811
   PubMed Web of Science ®Google Scholar
• Langerak A W, Molina T J, Lavender F L, Pearson D, Flohr T, Sambade C, et al. Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2007; 21: 222–229
   PubMed Web of Science ®Google Scholar
• van Krieken J H, Langerak A W, Macintyre E A, Kneba M, Hodges E, Sanz R G, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 concerted action BHM4-CT98-3936. Leukemia 2007; 21: 201–206
   PubMed Web of Science ®Google Scholar
• Droese J, Langerak A W, Groenen P J, Bruggemann M, Neumann P, Wolvers-Tettero I L, et al. Validation of BIOMED-2 multiplex PCR tubes for detection of TCRB gene rearrangements in T-cell malignancies. Leukemia 2004; 18: 1531–1538
   PubMed Web of Science ®Google Scholar
• Sandberg Y, Verhaaf B, van Gastel-Mol E J, Wolvers-Tettero I L, de Vos J, Macleod R A, et al. Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes. Leukemia 2007; 21: 230–237
   PubMed Web of Science ®Google Scholar
• Bishu S, Quigley J M, Schmitz J, Bishu S R, Stemm R A, Olsasky S M, et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 2007; 48: 1531–1538
   PubMed Web of Science ®Google Scholar